Recursion Pharmaceuticals uses AI to expedite the laborious process of developing drugs. The company could benefit from industry-wide regulatory changes as well as its own clinical progress. However, ...

In the latest close session, Recursion Pharmaceuticals (RXRX) was down 5.42% at $5.23. The stock fell short of the S&P 500, which registered a loss of 0.38% for the day. Meanwhile, the Dow experienced ...

Recursion Pharmaceuticals, Inc. (NASDAQ:RXRX) is one of the Best Penny Stocks to Buy with the Highest Upside Potential. On September 10, Gil Blum from Needham reiterated a Buy rating on Recursion ...

How Recursion is leading a new era of AI-driven drug discovery AI drug discovery is not a new phenomenon – but it is evolving at an almost dizzying pace. Recursion is one of the earliest innovators in ...

We recently published 10 Big Names With Explosive Growth. Recursion Pharmaceuticals, Inc. (NASDAQ:RXRX) is one of the best performers on Wednesday. Recursion Pharmaceuticals jumped by 16.44 percent on ...

Recursion Pharmaceuticals (NASDAQ:RXRX), a $2.06 billion market cap biotech company, saw Chief Executive Officer Christopher Gibson sell 100,000 shares of Class A Common Stock on September 25, 2025, ...

We are actively working to enhance your experience by translating more content. However, please be aware that the page you are about to visit has not yet been translated. We appreciate your ...